Harnessing bioinformatics for designing a novel multiepitope peptide vaccine against breast cancer

Current Pharmaceutical Biotechnology

Volumn 17, Issue 12, 2016, Pages 1100-1114

  Mahmoodi, Shirin ^a   Nezafat, Navid ^b   Barzegar, Abolfazl ^c   Negahdaripour, Manica ^b,d   Nikanfar, Ali R ^e   Zarghami, Nosratollah ^a,e   Ghasemi, Younes ^b,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TABRIZ   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant; CTL response; Epitope; Humoral immunity; Immunoinformatics; Immunotherapy

Indexed keywords

BACTERIAL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HEPARANASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; PEPTIDE VACCINE; POR B PROTEIN; SURVIVIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; SUBUNIT VACCINE; TUMOR ANTIGEN;

ALLERGENICITY; ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; BREAST CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; MOLECULAR DOCKING; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SEQUENCE ANALYSIS; VACCINATION; ANIMAL; BIOLOGY; BREAST NEOPLASMS; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SUBUNIT;

EID: 85008397861     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201017666160914191106     Document Type: Article

References (84)

1. Kaumaya, P.T.P. A paradigm shift: Cancer therapy with peptidebased B-cell epitope and peptide immunotherapeutics targeting multiple solid tumor types and emerging concepts and validation of combination immunotherapy. Hum. Vaccin. Immunother., 2015, 11(6), 1368-1386.
2. Ernst, B.; Anderson, K.S. Immunotherapy for the treatment of breast cancer. Curr. Oncol. Rep., 2015, 17(2), 1-10.
3. Milani, A.; Sangiolo, D.; Aglietta, M.; Valabrega, G. Recent advances in the development of breast cancer vaccines. Breast Cancer, 2014, 6, 159.
4. Dougan, M.; Dranoff, G. Immunotherapy of cancer: Innate immune regulation and cancer immunotherapy; Springer, 2012; pp. 391-414.
5. Shariat, S.; Badiee, A.; Jalali, S.A. Mansourian, M.; Yazdani, M.; Mortazavi, S.A.; Jaafari, M.R. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett., 2014, 355(1), 54-60.
6. Milani, A.; Sangiolo, D.; Montemurro, F.; Aglietta, M. Valabrega, G. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann. Oncol., 2013, 24(7), 1740-1748.
7. Vergati, M.; Intrivici, C.; Huen, N.-Y.; Schlom, J.; Tsang, K.Y. Strategies for cancer vaccine development. Biomed. Res. Int., 2010, 2010.
8. Manijeh, M.; Mehrnaz, K.; Violaine, M.; Hassan, M.; Abbas, J. Mohammad, R.: In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines. Asian Pac. J. Cancer Prev., 2013, 14(10), 5973-5981.
9. Mahdavi, M.; Keyhanfar, M.; Jafarian, A.; Mohabatkar, H.; Rabbani, M.: Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer. Tumour. Biol., 2014, 35(12), 12049-12057.
10. Nezafat, N.; Ghasemi, Y.; Javadi, G.; Khoshnoud, M. J.; Omidinia, E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J. Theor. Biol., 2014, 349, 121-134.
11. Nath, S.; Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med., 2014, 20(6), 332-342.
12. Zhang, J.; Yang, J.-M.; Wang, H.-J.; Ru, G.-Q. Fan, D.-M. Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS One, 2013, 8(1), 52940.
13. Gomes, A.M.; Stelling, M.P.; Pavão, M.S. Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed. Res. Int., 2013, 2013.
14. Sah, N.; Khan, Z.; Khan, G.; Bisen, P. Structural, functional and therapeutic biology of survivin. Cancer Lett., 2006, 244(2), 164-171.
15. Harao, M.; Mittendorf, E.A.; Radvanyi, L.G. Peptide-based vaccination and induction of cd8+ t-cell responses against tumor antigens in breast cancer. BioDrugs, 2015, 29(1), 15-30.
16. Farhadi, T.; Nezafat, N.; Ghasemi, Y.; Karimi, Z.; Hemmati, S.; Erfani, N. Designing of complex multi-epitope peptide vaccine based on omps of Klebsiella pneumoniae: An in silico Approach. Int. J. Pept. Res. Ther., 2015, 1-17.
17. Slingluff, C.L. Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J., 2011, 17(5), 343.
18. Toussi, D.N.; Massari, P. Immune adjuvant effect of molecularlydefined toll-like receptor ligands. Vaccines, 2014, 2(2), 323-353.
19. Awasthi, S. Toll-like receptor-4 modulation for cancer immunotherapy. Front. Immunol., 2014, 5.
20. Steinle, A.; Cerwenka, A. MULT1plying cancer immunity. Science, 2015, 348(6230), 45-46.
21. Mamessier, E.; Sylvain, A.; Thibult, M.-L. Houvenaeghel, G.; Jacquemier, J.; Castellano, R.; Gonçalves, A.; André, P.; Romagné, F.; Thibault, G. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest., 2011, 121(9), 3609.
22. Spear, P.; Wu, M.-R. Sentman, M.-L.; Sentman, C.L. NKG2D ligands as therapeutic targets. Cancer Immun. Arch.2013, 13(2), 8.
23. Samarakoon, A.; Chu, H.; Malarkannan, S. Murine NKG2D ligands:“double, double toil and trouble”. Mol. Immunol., 2009, 46(6), 1011-1019.
24. Obeidy, P.; Sharland, A.F. NKG2D and its ligands. Int. J. Biochem. Cell Biol., 2009, 41(12), 2364-2367.
25. Kotturi, H.; Li, J.; Branham-O'Connor, M.; Stickel, S.; Yu, X.; Wagner, T.; Wei, Y. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation. Gene Ther., 2008, 15(19), 1302-1310.
26. Swartz, M.A.; Iida, N.; Roberts, E.W.; Sangaletti, S.; Wong, M H.; Yull, F.E.; Coussens, L.M.; DeClerck, Y.A. Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res., 2012, 72(10), 2473-2480
27. Lorusso, G.; Rüegg, C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol., 2008, 130(6), 1091-1103.
28. Deng, W.; Gowen, B.G.; Zhang, L.; Wang, L.; Lau, S.; Iannello, A.; Xu, J.; Rovis, T.L.; Xiong, N.; Raulet, D.H. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science, 2015, 348(6230), 136-139.
29. Tietje, A.; Li, J.; Yu, X.; Wei, Y. MULT1E/mIL-12: A novel bifunctional protein for natural killer cell activation. Gene Ther., 2014, 21(5), 468-475.
30. Dosztányi, Z.; Csizmok, V.; Tompa, P.; Simon, I. IUPred: Web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics, 2005, 21(16), 3433-3434.
31. Dosztányi, Z.; Mészáros, B.; Simon, I. ANCHOR: Web server for predicting protein binding regions in disordered proteins. Bioinformatics, 2009, 25(20), 2745-2746.
32. Grote, A.; Hiller, K.; Scheer, M.; Münch, R.; Nörtemann, B.; Hempel, D.C.; Jahn, D. JCat: A novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res., 2005, 33(2), 526-531.
33. Gasteiger, E.; Hoogland, C.; Gattiker, A.; Wilkins, M.R.; Appel, R.D.; Bairoch, A. Protein identification and analysis tools on the ExPASy server; Springer, 2005.
34. Parker, K.C.; Bednarek, M.A.; Coligan, J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol., 1994, 152(1), 163-175.
35. Zhang, Q.; Wang, P.; Kim, Y.; Haste-Andersen, P.; Beaver, J.; Bourne, P.E.; Bui, H.-H.; Buus, S.; Frankild, S.; Greenbaum, J. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res., 2008, 36(2), 513-518.
36. Singh, H.; Raghava, G. ProPred1: Prediction of promiscuous MHC Class-I binding sites. Bioinformatics, 2003, 19(8), 1009-1014.
37. Reche, P.A.; Glutting, J.-P.; Reinherz, E.L. Prediction of MHC class I binding peptides using profile motifs. Hum. Immunol., 2002, 63(9), 701-709.
38. Guan, P.; Doytchinova, I.A.; Zygouri, C.; Flower, D.R. MHCPred: A server for quantitative prediction of peptide–MHC binding. Nucleic Acids Res., 2003, 31(13), 3621-3624.
39. Bordner, A.J.; Mittelmann, H.D. Prediction of the binding affinities of peptides to class II MHC using a regularized thermodynamic model. BMC Bioinformatics, 2010, 11(1), 41.
40. Bhasin, M.; Raghava, G. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine, 2004, 22(23), 3195-3204.
41. Liu, I.-H.; Lo, Y.-S.; Yang, J.-M. PAComplex: a web server to infer peptide antigen families and binding models from TCR– pMHC complexes. Nucleic Acids Res., 2011, 434.
42. EL-Manzalawy, Y.; Dobbs, D.; Honavar, V.: Predicting linear B‐cell epitopes using string kernels. J. Mol. Recognit., 2008, 21(4), 243-255.
43. Kringelum, J. V.; Lundegaard, C.; Lund, O.; Nielsen, M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput. Biol., 2012, 8(12).
44. Ivanciuc, O.; Schein, C.H.; Braun, W. SDAP: Database and computational tools for allergenic proteins. Nucleic Acids Res., 2003, 31(1), 359-362.
45. Saha, S.; Raghava, G. AlgPred: Prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res., 2006, 34(2), 202-209.
46. Doytchinova, I.A.; Flower, D.R. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics, 2007, 8(1), 4.
47. Magnan, C.N.; Zeller, M.; Kayala, M.A.; Vigil, A.; Randall, A.; Felgner, P.L.; Baldi, P. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics, 2010, 26(23), 2936-2943.
48. Jenik, M.; Parra, R.G.; Radusky, L.G.; Turjanski, A.; Wolynes, P.G.; Ferreiro, D.U. Protein frustratometer: A tool to localize energetic frustration in protein molecules. Nucleic Acids Res., 2012, 447.
49. McGuffin, L.J.; Bryson, K.; Jones, D.T. The PSIPRED protein structure prediction server. Bioinformatics, 2000, 16(4), 404-405.
50. Kelley, L.A.; Mezulis, S.; Yates, C.M.; Wass, M.N.; Sternberg, M.J. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc., 2015, 10(6), 845-858.
51. Khoury, G.A.; Tamamis, P.; Pinnaduwage, N.; Smadbeck, J.; Kieslich, C.A.; Floudas, C.A. Princeton_TIGRESS: Protein geometry refinement using simulations and support vector machines. Proteins, 2014, 82(5), 794-814.
52. Wiederstein, M.; Sippl, M.J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res., 2007, 35(2), 407-410.
53. Lovell, S.C.; Davis, I.W.; Arendall, W.B.; de Bakker, P.I.; Word, J.M.; Prisant, M.G.; Richardson, J.S.; Richardson, D.C. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins, 2003, 50(3), 437-450.
54. Liithy, R.; Bowie, J.; Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature, 1992, 356(6364), 83-85.
55. Colovos, C.; Yeates, T.O. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci., 1993, 2(9), 1511.
56. Magnan, C.N.; Randall, A.; Baldi, P. SOLpro: Accurate sequencebased prediction of protein solubility. Bioinformatics, 2009, 25(17), 2200-2207.
57. Kozakov, D.; Hall, D.R.; Beglov, D.; Brenke, R.; Comeau, S.R.; Shen, Y.; Li, K.; Zheng, J.; Vakili, P.; Paschalidis, I.C.: Achieving reliability and high accuracy in automated protein docking: ClusPro, PIPER, SDU, and stability analysis in CAPRI rounds 13– 19. Proteins, 2010, 78(15), 3124-3130.
58. Mashiach, E.; Schneidman-Duhovny, D.; Andrusier, N.; Nussinov, R.; Wolfson, H.J. FireDock: A web server for fast interaction refinement in molecular docking. Nucleic Acids Res., 2008, 36(2), 229-232.
59. Brusic, V.; Rudy, G.; Harrison, L.C. MHCPEP, a database of MHC-binding peptides: Update 1997. Nucleic Acids Res., 1998, 26(1), 368-371.
60. Bhasin, M.; Singh, H.; Raghava, G. MHCBN: A comprehensive database of MHC binding and non-binding peptides. Bioinformatics, 2003, 19(5), 665-666.
61. Rammensee, H.-G.; Bachmann, J.; Emmerich, N.P.N.; Bachor, O.A.; Stevanović, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 1999, 50(3-4), 213-219.
62. Blythe, M.J.; Doytchinova, I.A.; Flower, D.R. JenPep: A database of quantitative functional peptide data for immunology. Bioinformatics, 2002, 18(3), 434-439.
63. Saha, S.; Bhasin, M.; Raghava, G.P. Bcipep: A database of B-cell epitopes. BMC Genomics, 2005, 6(1), 79.
64. Arteaga, C.L.; Sliwkowski, M.X.; Osborne, C.K.; Perez, E.A.; Puglisi, F.; Gianni, L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol., 2012, 9(1), 16-32.
65. Ladjemi, M.Z.; Jacot, W.; Chardès, T.; Pèlegrin, A.; Navarro-Teulon, I. Anti-HER2 vaccines: New prospects for breast cancer therapy. Cancer Immunol. Immunother., 2010, 59(9), 1295-1312.
66. Ghasemi, Y.; Dabbagh, F.; Rasoul-Amini, S.; Haghighi, A.B.; Morowvat, M.H. The possible role of HSPs on Behçet's disease: A bioinformatic approach. Comput. Biol. Med., 2012, 42(11), 1079-1085.
67. Shahbazi, M.; Haghkhah, M.; Rahbar, M. R.; Nezafat, N.; Ghasemi, Y. In silico sub-unit hexavalent peptide vaccine against an staphylococcus aureus biofilm-related infection. Int. J. Pept. Res. Ther., 2015, 1-17.
68. Farhadi, T.; Nezafat, N.; Ghasemi, Y. In silico phylogenetic analysis of Vibrio cholerae isolates Int. J. Comput. Biol. Drug Des., 2015, 8(1), 62-74. based on three housekeeping genes.
69. Curigliano, G.; Spitaleri, G.; Pietri, E.; Rescigno, M.; De Braud, F.; Cardillo, A.; Munzone, E.; Rocca, A.; Bonizzi, G.; Brichard, V. Breast cancer vaccines: A clinical reality or fairy tale? Ann. Oncol., 2006, 17(5), 750-762.
70. Yang, X.; Yu, X. An introduction to epitope prediction methods and software. Rev. Med. Virol., 2009, 19(2), 77-96.
71. Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res., 2009, 15(17), 5323-5337.
72. Neefjes, J.; Jongsma, M. L.; Paul, P.; Bakke, O.: Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol., 2011, 11(12), 823-836.
73. Gilboa, E. The promise of cancer vaccines. Nat. Rev. Cancer, 2004, 4(5), 401-411.
74. Lizée, G.; Overwijk, W. W.; Radvanyi, L.; Gao, J.; Sharma, P.; Hwu, P. Harnessing the power of the immune system to target cancer. Annu. Rev. Med., 2013, 64, 71-90.
75. Reuschenbach, M.; von Knebel Doeberitz, M.; Wentzensen, N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother., 2009, 58(10), 1535-1544.
76. Matijevic, T.; Pavelic, J. Toll-like receptors: cost or benefit for cancer? Curr. Pharm. Des., 2010, 16(9), 1081-1090.
77. Conroy, H.; Marshall, N.; Mills, K. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene, 2008, 27(2), 168-180.
78. Basith, S.; Manavalan, B.; Lee, G.; Kim, S.G.; Choi, S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin. Ther. Pat., 2011, 21(6), 927-944.
79. Kattner, C.; Toussi, D. N.; Zaucha, J.; Wetzler, L. M.; Rüppel, N.; Zachariae, U.; Massari, P.; Tanabe, M. Crystallographic analysis of Neisseria meningitidis PorB extracellular loops potentially implicated in TLR2 recognition. J. Struct. Biol., 2014, 185(3), 440-447.
80. Chen, X.; Zaro, J. L.; Shen, W.-C. Fusion protein linkers: property, design and functionality. Adv. Drug Deliv. Rev., 2013, 65(10), 1357-1369.
81. Yano, A.; Onozuka, A.; Asahi-Ozaki, Y.; Imai, S.; Hanada, N.; Miwa, Y.; Nisizawa, T. An ingenious design for peptide vaccines. Vaccine, 2005, 23(17), 2322-2326.
82. Dolenc, I.; Seemüller, E.; Baumeister, W. Decelerated degradation of short peptides by the 20S proteasome. FEBS Lett., 1998, 434(3), 357-361.
83. McFarland, B. J.; Kortemme, T.; Shuyuarn, F.Y.; Baker, D.; Strong, R.K. Symmetry recognizing asymmetry: Analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure, 2003, 11(4), 411-422.
84. Ferreiro, D.U.; Hegler, J.A.; Komives, E.A.; Wolynes, P.G. Localizing frustration in native proteins and protein assemblies. Proc. Natl. Acad. Sci., 2007, 104(50), 19819-19824.